Matches in SemOpenAlex for { <https://semopenalex.org/work/W2112551403> ?p ?o ?g. }
Showing items 1 to 59 of
59
with 100 items per page.
- W2112551403 abstract "Summary1. Eighty-nine patients were observed for periods up to two years by the same observer in nearly every case. After eliminating failures and those unsuited to the study, the remaining 58 have continued for periods up to 24 months with a mean duration of 17.4 months.2. Overall, HB 419 was effective in lowering blood glucose levels in only 27 of the 58 (46.5 %) who continued, however, when the 22 persons also treated with biguanide were eliminated, of the 36 who continued with HB419 alone, 27 (75.0 %) were classified as “satisfactory”. This compares most favourably with the experience using other oral hypoglycaemic agents.3. Surprisingly, the patient who did not respond to HB 419 (Daonil) alone, did not improve with the addition of biguanide. This is contrary to previous reports and suggests that when this preparation is effective, the effect is maximal, but when it fails, adding other compounds adds nothing.4. A dosage of 5 to 20 mg is sufficient for most patients and increased dose levels beyond 20 mg does little or nothing for those who did not respond. Twenty-nine of the 36 using only Daonil compound continue with a single daily dose.5. HB 419 was only rarely effective in patients who had been failures with maximal doses of other sulphonylurea compounds in this series.6. There have been no side effects or drug-related toxicity in this series.7. At present the secondary failure rate is remarkably low although this may increase over a longer period of time.8. According to this clinical investigation of HB 419 (Daonil) while there does not appear to be a clear-cut advantage over other available sulphonylurea compounds there are enough promising facets such as low dose, freedom from side effects and toxicity, single dosage and low rate of secondary failure that longer term observations may prove this to be the equal of, and possibly superior to, the other presently known sulphonylurea compounds." @default.
- W2112551403 created "2016-06-24" @default.
- W2112551403 creator A5010475083 @default.
- W2112551403 creator A5021568587 @default.
- W2112551403 creator A5048350336 @default.
- W2112551403 date "1971-08-01" @default.
- W2112551403 modified "2023-09-25" @default.
- W2112551403 title "Glibenclamide (HB 419, Daonil) in the Clinical Practice of Diabetes*" @default.
- W2112551403 cites W2007039246 @default.
- W2112551403 cites W2047967013 @default.
- W2112551403 cites W2336242705 @default.
- W2112551403 doi "https://doi.org/10.1111/j.1445-5994.1971.tb02576.x" @default.
- W2112551403 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/5005132" @default.
- W2112551403 hasPublicationYear "1971" @default.
- W2112551403 type Work @default.
- W2112551403 sameAs 2112551403 @default.
- W2112551403 citedByCount "1" @default.
- W2112551403 crossrefType "journal-article" @default.
- W2112551403 hasAuthorship W2112551403A5010475083 @default.
- W2112551403 hasAuthorship W2112551403A5021568587 @default.
- W2112551403 hasAuthorship W2112551403A5048350336 @default.
- W2112551403 hasConcept C126322002 @default.
- W2112551403 hasConcept C134018914 @default.
- W2112551403 hasConcept C2777688063 @default.
- W2112551403 hasConcept C2779768347 @default.
- W2112551403 hasConcept C2780035454 @default.
- W2112551403 hasConcept C2780323712 @default.
- W2112551403 hasConcept C29730261 @default.
- W2112551403 hasConcept C555293320 @default.
- W2112551403 hasConcept C71924100 @default.
- W2112551403 hasConcept C98274493 @default.
- W2112551403 hasConceptScore W2112551403C126322002 @default.
- W2112551403 hasConceptScore W2112551403C134018914 @default.
- W2112551403 hasConceptScore W2112551403C2777688063 @default.
- W2112551403 hasConceptScore W2112551403C2779768347 @default.
- W2112551403 hasConceptScore W2112551403C2780035454 @default.
- W2112551403 hasConceptScore W2112551403C2780323712 @default.
- W2112551403 hasConceptScore W2112551403C29730261 @default.
- W2112551403 hasConceptScore W2112551403C555293320 @default.
- W2112551403 hasConceptScore W2112551403C71924100 @default.
- W2112551403 hasConceptScore W2112551403C98274493 @default.
- W2112551403 hasLocation W21125514031 @default.
- W2112551403 hasLocation W21125514032 @default.
- W2112551403 hasOpenAccess W2112551403 @default.
- W2112551403 hasPrimaryLocation W21125514031 @default.
- W2112551403 hasRelatedWork W1563850031 @default.
- W2112551403 hasRelatedWork W2032287785 @default.
- W2112551403 hasRelatedWork W2050431722 @default.
- W2112551403 hasRelatedWork W2167444163 @default.
- W2112551403 hasRelatedWork W2184570932 @default.
- W2112551403 hasRelatedWork W2290076351 @default.
- W2112551403 hasRelatedWork W2374391052 @default.
- W2112551403 hasRelatedWork W2379319452 @default.
- W2112551403 hasRelatedWork W2383009242 @default.
- W2112551403 hasRelatedWork W3036934084 @default.
- W2112551403 isParatext "false" @default.
- W2112551403 isRetracted "false" @default.
- W2112551403 magId "2112551403" @default.
- W2112551403 workType "article" @default.